It was a long time coming but third time’s the charm for flibanserin, a revolutionary new drug to combat female sexual dysfunction. The drug is the first medical treatment for the condition to gain approval by the Food and Drug Administration.
The advisory panel of medical experts looking into research about the drug voted 16 to 8 to recommended approval of the pill, although they added several safety restrictions. The restriction address concerns around low blood pressure, fatigue, and fainting.
Flibanserin is a pink pill taken every day at bedtime. It was specifically approved to treat lack of sexual desire in premenopausal women that cannot be linked to disease or other known causes. Approximately 7 percent of premenopausal women have this condition, known as hypoactive sexual desire disorder.
The drug’s multi-rejection approval process makes it one of the most controversial drugs in some time to clear FDA approval Women’s rights groups were particularly vocal about getting the drug approved, which may have influenced the FDA’s decision.
Stay Connected
